Recent News

• 04.14.2025 - Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks
• 03.25.2025 - Soligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 Variants
• 02.04.2025 - Soligenix to Present at BIO CEO & Investor Conference
• 01.16.2025 - Soligenix to Present at Upcoming Investor Conferences
• 01.14.2025 - HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma
• 01.14.2025 - HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma
• 12.16.2024 - Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

Recent Filings

• 03.28.2025 - 8-K Current report
• 03.26.2025 - EFFECT Notice of Effectiveness
• 03.26.2025 - EFFECT Notice of Effectiveness
• 03.26.2025 - EFFECT Notice of Effectiveness
• 03.21.2025 - POS AM Post-Effective amendments for registration statement
• 03.21.2025 - POS AM Post-Effective amendments for registration statement
• 03.21.2025 - POS AM Post-Effective amendments for registration statement
• 03.21.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 02.10.2025 - 8-K Current report
• 12.13.2024 - 4 Statement of changes in beneficial ownership of securities